Literature DB >> 23856780

Chimeric Cyanovirin-MPER recombinantly engineered proteins cause cell-free virolysis of HIV-1.

Mark Contarino1, Arangassery R Bastian, Ramalingam Venkat Kalyana Sundaram, Karyn McFadden, Caitlin Duffy, Vamshi Gangupomu, Michelle Baker, Cameron Abrams, Irwin Chaiken.   

Abstract

Human immunodeficiency virus (HIV) is the primary etiologic agent responsible for the AIDS pandemic. In this work, we used a chimeric recombinant protein strategy to test the possibility of irreversibly destroying the HIV-1 virion using an agent that simultaneously binds the Env protein and viral membrane. We constructed a fusion of the lectin cyanovirin-N (CVN) and the gp41 membrane-proximal external region (MPER) peptide with a variable-length (Gly4Ser)x linker (where x is 4 or 8) between the C terminus of the former and N terminus of the latter. The His-tagged recombinant proteins, expressed in BL21(DE3)pLysS cells and purified by immobilized metal affinity chromatography followed by gel filtration, were found to display a nanomolar efficacy in blocking BaL-pseudotyped HIV-1 infection of HOS.T4.R5 cells. This antiviral activity was HIV-1 specific, since it did not inhibit cell infection by vesicular stomatitis virus (VSV) or amphotropic-murine leukemia virus. Importantly, the chimeric proteins were found to release intraviral p24 protein from both BaL-pseudotyped HIV-1 and fully infectious BaL HIV-1 in a dose-dependent manner in the absence of host cells. The addition of either MPER or CVN was found to outcompete this virolytic effect, indicating that both components of the chimera are required for virolysis. The finding that engaging the Env protein spike and membrane using a chimeric ligand can destabilize the virus and lead to inactivation opens up a means to investigate virus particle metastability and to evaluate this approach for inactivation at the earliest stages of exposure to virus and before host cell encounter.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23856780      PMCID: PMC3811417          DOI: 10.1128/AAC.00309-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Potent strategy to inhibit HIV-1 by binding both gp120 and gp41.

Authors:  Ioannis Kagiampakis; Arbi Gharibi; Marie K Mankowski; Beth A Snyder; Roger G Ptak; Kristabelle Alatas; Patricia J LiWang
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

3.  Designed oligomers of cyanovirin-N show enhanced HIV neutralization.

Authors:  Jennifer R Keeffe; Priyanthi N P Gnanapragasam; Sarah K Gillespie; John Yong; Pamela J Bjorkman; Stephen L Mayo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-28       Impact factor: 11.205

Review 4.  Microbicides: still a long road to success.

Authors:  Christophe Vanpouille; Anush Arakelyan; Leonid Margolis
Journal:  Trends Microbiol       Date:  2012-06-15       Impact factor: 17.079

5.  Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120.

Authors:  Arangassery R Bastian; Karyn McFadden; Caitlin Duffy; Srivats Rajagopal; Mark R Contarino; Elisabeth Papazoglou; Irwin Chaiken
Journal:  ChemMedChem       Date:  2011-06-28       Impact factor: 3.466

Review 6.  The antiviral protein cyanovirin-N: the current state of its production and applications.

Authors:  Sheng Xiong; Jun Fan; Kaio Kitazato
Journal:  Appl Microbiol Biotechnol       Date:  2010-02-17       Impact factor: 4.813

7.  Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Authors:  Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall
Journal:  Lancet       Date:  2010-07-16       Impact factor: 79.321

Review 8.  HIV: cell binding and entry.

Authors:  Craig B Wilen; John C Tilton; Robert W Doms
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

9.  Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.

Authors:  David C Montefiori
Journal:  Curr Protoc Immunol       Date:  2005-01

10.  Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1.

Authors:  Jérôme Coutant; Huifeng Yu; Marie-Jeanne Clément; Annette Alfsen; Flavio Toma; Patrick A Curmi; Morgane Bomsel
Journal:  FASEB J       Date:  2008-09-05       Impact factor: 5.191

View more
  9 in total

1.  Lytic Inactivation of Human Immunodeficiency Virus by Dual Engagement of gp120 and gp41 Domains in the Virus Env Protein Trimer.

Authors:  Bibek Parajuli; Kriti Acharya; Reina Yu; Brendon Ngo; Adel A Rashad; Cameron F Abrams; Irwin M Chaiken
Journal:  Biochemistry       Date:  2016-10-27       Impact factor: 3.162

2.  Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.

Authors:  Arangassery Rosemary Bastian; Aakansha Nangarlia; Lauren D Bailey; Andrew Holmes; R Venkat Kalyana Sundaram; Charles Ang; Diogo R M Moreira; Kevin Freedman; Caitlin Duffy; Mark Contarino; Cameron Abrams; Michael Root; Irwin Chaiken
Journal:  J Biol Chem       Date:  2014-11-04       Impact factor: 5.157

3.  Peptide triazole inactivators of HIV-1: how do they work and what is their potential?

Authors:  Irwin Chaiken; Adel A Rashad
Journal:  Future Med Chem       Date:  2015-11-24       Impact factor: 3.808

4.  Roles of variable linker length in dual acting virucidal entry inhibitors on HIV-1 potency via on-the-fly free energy molecular simulations.

Authors:  Steven T Gossert; Bibek Parajuli; Irwin Chaiken; Cameron F Abrams
Journal:  Protein Sci       Date:  2020-09-29       Impact factor: 6.725

5.  Roles of conserved tryptophans in trimerization of HIV-1 membrane-proximal external regions: Implications for virucidal design via alchemical free-energy molecular simulations.

Authors:  Steven T Gossert; Bibek Parajuli; Irwin Chaiken; Cameron F Abrams
Journal:  Proteins       Date:  2018-04-19

6.  Restricted HIV-1 Env glycan engagement by lectin-reengineered DAVEI protein chimera is sufficient for lytic inactivation of the virus.

Authors:  Bibek Parajuli; Kriti Acharya; Harry C Bach; Bijay Parajuli; Shiyu Zhang; Amos B Smith; Cameron F Abrams; Irwin Chaiken
Journal:  Biochem J       Date:  2018-03-09       Impact factor: 3.857

7.  Functionalized High Mannose-Specific Lectins for the Discovery of Type I Mannosidase Inhibitors.

Authors:  Suresh E Kurhade; Jack D Weiner; Fei Philip Gao; Mark P Farrell
Journal:  Angew Chem Int Ed Engl       Date:  2021-04-26       Impact factor: 16.823

8.  Conformational plasticity underlies membrane fusion induced by an HIV sequence juxtaposed to the lipid envelope.

Authors:  Igor de la Arada; Johana Torralba; Igor Tascón; Adai Colom; Iban Ubarretxena-Belandia; José L R Arrondo; Beatriz Apellániz; José L Nieva
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

9.  Linker-extended native cyanovirin-N facilitates PEGylation and potently inhibits HIV-1 by targeting the glycan ligand.

Authors:  Jia Chen; Dane Huang; Wei Chen; Chaowan Guo; Bo Wei; Chongchao Wu; Zhou Peng; Jun Fan; Zhibo Hou; Yongsheng Fang; Yifei Wang; Kaio Kitazato; Guoying Yu; Chunbin Zou; Chuiwen Qian; Sheng Xiong
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.